期刊文献+

拓扑替康对宫颈癌细胞系HeLa放射增敏作用的研究 被引量:1

Radiosensitization effect of Topotecan on cervical carcinoma cell line HeLa.
下载PDF
导出
摘要 目的:探讨拓扑替康对宫颈癌细胞系HeLa的放射增敏作用及其作用机制。方法:用MTT法和克隆形成分析实验检测拓扑替康对HeLa细胞放射增敏的影响,流式细胞仪检测细胞凋亡率及细胞周期。结果:放疗同时给予0.1、0.5、1.0、5.0μg/m l拓扑替康的放射增敏比分别为1.21、1.40、1.66、1.96;放疗同时及放疗后3h给予拓扑替康组增敏效果最佳,放疗前和放疗后6h以后给予拓扑替康组细胞生存分数与此差异有统计学意义(P<0.05);流式细胞仪检测单化组、单放组和增敏组放疗后24h和48h细胞凋亡率分别为:12.30%和17.00%,16.13%和21.90%,25.13%和34.43%;单放组和不同剂量拓扑替康增敏组G2/M期细胞比例增加。结论:拓扑替康对宫颈癌细胞系HeLa有放射增敏作用,且有剂量依赖性和用药时间选择性,其放射增敏机制可能与HeLa细胞放射后损伤性修复、细胞凋亡及G2/M期阻滞相关。 Objective:To investigate the radiosensitization effect and the mechanism of Topotecan on cervical carcinoma cell line HeLa. Methods:The radiosensitization effect of different doses and different treatment duration of Topotecan on HeLa cell line was evaluated by MTT test and clone formation essays. Apoptosis rate of defferent groups and cell cycles were calculated by flow cytometry. Results: Radiosensitization enhancement ratios of 0. 1,0.5,1.0 and 5.0μg/ml Topotecan in combination with radiotherapy were 1.21,1.40,1.66 and 1.96, respectively. Additions of Topotecan simultaneously or 3 hours after radiotherapy achieve optimal radiosensitization effects and had significant differences with that when Topotecan could be added right before or 6 hours after radiotherapy ( P 〈 0.05 ). Apoptosis rates at 24 hours and 48 hours of the chemotherapy only group, the radiotherapy only group and the combination group by flow cytometry were 12.30% and 17.00% ,16.13% and 21.90% ,25.13% and 34.43% ,respectively. Cells in G2/M period increased in radiotherapy only group and different doses of Topotecan groups. Conclusion:Topotecan has radiosensitization effect on cervical carcinoma HeLa cells, which shows dose dependent and treatment duration dependent characteristic. This effect is probably caused by post-injury repair,apoptosis and G2/M block of HeLa cells.
出处 《现代妇产科进展》 CSCD 北大核心 2006年第5期332-335,共4页 Progress in Obstetrics and Gynecology
关键词 宫颈肿瘤 HELA细胞 拓扑替康 辐射增敏药 细胞凋亡 Cervix neosplasms HeLa cells Topotecan Radiation-sensitiziting agent Apoptosis
  • 相关文献

参考文献13

二级参考文献81

  • 1李玲,隋丽华.IIb期子宫颈癌患者术前动脉插管化疗的十年观察[J].中华妇产科杂志,1989,24(1):37-39. 被引量:19
  • 2董菊颖,卢玉波.腹壁下动脉插管化疗在妇科恶性肿瘤的应用[J].云南医药,1997,18(2):87-89. 被引量:1
  • 3WALL JG, BENEDETTI JK, O'RROUIKE MA, et al. Phase II trial to in hepatocellular carcinoma: a southwest oncology group study[J]. Invest New Drugs, 1997,15(3) :257-260.
  • 4BROWN ZA, BENEDETTI JK, WATTS DH, et al. Phase II trial to topotecan in hepatocellular carcinoma: a southwest oncology group study[J ]. Invest New Drugs, 1997,15(3):257-260.
  • 5KANCHERLA RR, NAIR JS, AHMED T, et al. Evaluation of topotecan and etoposide for Non-Hodgkin Lymphoma[ J ]. Cancer, 2001, 91(3) : 463-471.
  • 6MUDERSPACH LI, BLESSING JA, LEVENBACK C, et al. A phase Ⅱ study of Topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study[J]. Gynecol oncol, 2000, 81(2):213-215.
  • 7ARDIZZONI A, HANSEN H, DOMBERNOWSKY P, et al.Topotecan,a new active drug in the second-line treatment of small-cell lung cancer: a phase lI study in patients with refractory and sensitive diease[J]. J Clin Oncol,1997,15(5) :2090-2096.
  • 8SCHILLER JH, KIM KM, HUTSON P, et al. Phase Ⅱ study to topotecan in patients with extensive stage small cell carcinoma of the lung: an eastern cooperative oncolgy group trail[J]. J Clin Oncol, 1996,14 (8) : 2345-2352.
  • 9von PAWEL J ,SCHILLER JH, SHEPFERD FA, et al. Topotecan versus cyclophosphmide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J]. J Clin Oncol,1999,17(2) : 658-667.
  • 10HAINSWORTH JD, BORRIS HA, MORRISSEY LH, et al.Phase I trial of paclitaxel , earboplatin, and topoteean with or without filgrastim (granulocye-colony stimulating factor ) in the treatment of patients with advanced, refractory cancer[J ]. Cancer, 1999,85(5) : 1179-1185.

共引文献11

同被引文献9

  • 1[1]Downs LS Jr,Judson PL,Argenta PA,et al.Aprospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.Cancer,2008,112(2):331-339.
  • 2[2]Choi HJ,Cho BC,Shin SJ,et al.Combinationof topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung eancer following irinotecan and platinum first-line chemotherapy.Cancer Chemother Pharmacol,2008,61(2):309-313.
  • 3[3]Abushahin F,Singh DK,Lurain JR,et al.Weekly topotecan for recurrent platintnn resistant ovarian cancer.Gyneool Oncol,2008,108(1):53-57.
  • 4[4]Bernier-Chastagner V,Grill J,Doz F,et al.Topoteean as a radiosensitizer in the treatment of children with malignant diffuse brainstem glionms:results of a French Society of Paediatric Oncology Phase Ⅱ Study.Cancer,2005,104(12):2792-2797.
  • 5[5]Long HJ 3rd,Monk BJ,Huang HQ,et al.Clincal results and quality of life analysis for the MVAC combination(methotrexate,vinblastine,doxorubiein,and cisplatin)in carcinoma of the uterine cervix:a Gynecologic Onoology Group Study.Gynecol Oncol,2006,100(3):537-543.
  • 6[6]Brave M,Dagher R,Farrell A,et al.Topotecan in combination with cisplatin for the treatment of stage Ⅳ B,recurrent,or persistent cervical cancer.Oncology(Williston Park),2006,20(11):1401-1404,1406-1415.
  • 7[7]Rose PG,Bundy BN,Watkins EB,et al.Concurrent eisplatinbased radiotherapy and chemotherapy for locally advanced cervical cancer.N Engl J Med,1999,340(15):1144-1153.
  • 8[8]Patd SH,Ajlouni M,Chapman R,et al.A prospective phase Ⅱ study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiothempy(ART)in locally advanced non-small cell lung cancer(NSCLC).J rhorac Oncol,2007,2(9):831-837.
  • 9[9]Bell MC,Davidson SA,Mathis JM,et al.Topotecan concomitant with primary brachythempy radiation in patients with cervical carcinoma:a phase Ⅰ trial.Gyneeol Oncol,2001,80(2):128-131.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部